Torshin et al (2019) [Cerebrolysin peptides as mood stabilizers] https://pubmed.ncbi.nlm.nih.gov/31994517/ Editor’s note: The Cochrane Review on cerebrolysin for vascular dementia was updated in November 2019 and highlights a continuing evidence gap, with no new studies found for inclusion in the review. A. Ozkizilcik et al., “Nanodelivery of cerebrolysin reduces pathophysiology of Parkinson’s disease,” Prog. Brain Res., vol. 245, pp. 201–246, 2019, doi: 10.1016/bs.pbr.2019.03.014. Research in patients suffering from dementia suggests that Cerebrolysin can improve global outcome measures and cognitive ability[2], [3]. There is interest in using the extract in combination with cholinesterase inhibitors to perhaps achieve a synergistic effect.

A few small clinical trials have reported that cerebrolysin can improve cognitive function in older people with memory problems and in those with schizophrenia, although the effects are modest. In a trial with schizophrenia patients, cerebrolysin treatment improved cognition and memory [10]. Another trial of older adults with memory loss found that a peptide preparation derived from cerebrolysin improved memory performance but not verbal fluency [11]. The effect on memory was lower than that of currently approved drugs for Alzheimer's disease. An uncontrolled clinical trial reported that healthy elderly people had better memory performance after one dose of cerebrolysin but this result could have been caused by the placebo effect [12]. Onose G, Mureşanu DF, Ciurea AV, Daia Chendreanu C, Mihaescu AS, Mardare DC, Andone I, Spânu A, Popescu C, Dumitrescu A, Popescu M, Grigorean V, Ungur B, Marinescu F, Colibbeanu I, Onose L, Haras M, Sandu A, Spircu T (2009) Neuroprotective and consequent neurorehabilitative clinical outcomes, in patients treated with the pleiotropic drug cerebrolysin. J Med Life 2(4):350–360

Acknowledgments

Razavi S, Nazem G, Mardani M, Esfandiari E, Esfahani S, Salehi H (2015) Neurotrophic factors and their effects in the treatment of multiple sclerosis. Adv Biomed Res 4(1). https://doi.org/10.4103/2277-9175.151570 Xiao S, Xue H, Li G et al. (2012) Therapeutic effects of cerebrolysin added to risperidone in patients with schizophrenia dominated by negative symptoms. Aust N Z J Psychiatry 46, 153-160. Thome J, Doppler E (2012) Safety profile of Cerebrolysin: clinical experience from dementia and stroke trials. Drugs of today 48 Suppl A, 63-69.

Panisset M, Gauthier S, Moessler H, Windisch M, Cerebrolysin Study G (2002) Cerebrolysin in Alzheimer’s disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent. J Neural Transm (Vienna) 109(7-8):1089–1104. https://doi.org/10.1007/s007020200092 Gharagozli K, Harandi AA, Houshmand S, Akbari N, Muresanu DF, Vester J, Winter S, Moessler H (2017) Efficacy and safety of Cerebrolysin treatment in early recovery after acute ischemic stroke: a randomized, placebo-controlled, double-blinded, multicenter clinical trial. J Med Life 10(3):153–160 Alvarez XA, Alvarez I, Martinez A, Romero I, Benito C, Suarez I, Mourente S, Fantini M, Figueroa J, Aleixandre M, Linares C, Muresanu D, Winter S, Moessler H (2020) Serum VEGF predicts clinical improvement induced by Cerebrolysin plus donepezil in patients with advanced Alzheimer’s disease. Int J Neuropsychopharmacol. https://doi.org/10.1093/ijnp/pyaa046 Hartbauer et al (2001) Effects of Cerebrolysin on the outgrowth and protection of processes of cultured brain neurons https://www.ncbi.nlm.nih.gov/pubmed/11459078

What is the Optimal Cerebrolysin Dosage?

Optimum doses of Cerebrolysin are safe and may cause side effects as listed above. However, toxic doses can result in severe palpitations and vomiting. Where to buy online Cerebrolysin: Cerebrolysin was first developed in Austria in 1949. It has since been widely used in the eastern part of the world, particularly Russia and China. It has been considered a Vital and Essential Medicine in Russia since 1992. Kushner D (1998) Mild traumatic brain injury: toward understanding manifestations and treatment. Arch Intern Med 158(15):1617–1624. https://doi.org/10.1001/archinte.158.15.1617 S Gavrilova, A Alvarez (2021) Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer’s disease: 30 years of clinical use https://pubmed.ncbi.nlm.nih.gov/32808294/